Profound Medical Corp. Unveils Key Financial Insights Soon
Profound Medical Set to Release Third Quarter Financial Results
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leading medical device company specializing in innovative, incision-free therapies for treating disease, is gearing up to deliver its financial results for the third quarter of 2024. Investors and stakeholders will be eagerly awaiting the insights that come with these results, expected to be released following the market's close.
Conference Call Details
The management team at Profound will hold a conference call at 4:30 p.m. ET to discuss the financial performance from the last quarter and share updates on the company's strategic direction.
Why Attend the Conference Call?
This event will not only cover the latest financial data but also shed light on ongoing and upcoming projects that could shape the company's future. Stakeholders will have an opportunity to engage with Profound’s leadership and gain valuable insights into their innovative approaches and market strategies.
About Profound Medical Corp.
As a commercial-stage medical device company, Profound is committed to bringing advanced therapies to patients without the need for surgeries. The flagship product, TULSA-PRO®, represents a significant breakthrough in prostate disease treatment. This technology combines real-time MRI imaging and robotically-controlled ultrasound for precise tissue ablation. TULSA-PRO® allows for minimal disruption while effectively treating conditions such as prostate cancer and benign prostatic hyperplasia (BPH).
The TULSA procedure is noteworthy for its unique approach. It delivers heat to the targeted tissue without requiring incisions or extensive recovery periods. This is particularly beneficial for patients who may be anxious about traditional surgical options. As a result, TULSA-PRO® is carving a niche as a go-to treatment method that meets the needs of varying patient profiles and conditions.
Innovative Therapeutics on the Horizon
In addition to TULSA-PRO®, Profound is also advancing Sonalleve®, an exceptional technology designed for treating uterine fibroids and alleviating pain from bone metastases. Recently sanctioned in multiple jurisdictions, Sonalleve® represents a growing sector within the company's portfolio as they explore further applications of the technology.
With its existing approvals and clinical evidence supporting its efficacy, Sonalleve® is also setting its sights on additional markets where non-invasive ablation techniques could revolutionize treatment options for various forms of cancer.
Looking Ahead: Profound’s Growth Strategy
As Profound Medical Corp. prepares for its pivotal financial call, there is significant intrigue about the upcoming developments and how they align within the company's overarching growth strategy. The focus remains on establishing a stronger presence in the non-invasive treatment market and expanding their portfolio of innovative medical technologies.
By continuously enhancing their product offerings, Profound is well-positioned to take advantage of a growing demand for less invasive treatment methods, catering to a diverse patient population.
Contact Information
For more information about Profound Medical's upcoming conference call and developments, please reach out to:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Frequently Asked Questions
What is the main focus of Profound Medical Corp.?
Profound Medical Corp. specializes in developing incision-free therapies for ablation of diseased tissue, particularly for prostate-related conditions.
When will Profound Medical announce its financial results?
The financial results for the third quarter of 2024 will be released after market close on November 7, 2024.
What are the key products offered by Profound Medical?
The key products include TULSA-PRO® for prostate treatments and Sonalleve® for uterine fibroid treatments and pain management.
How can investors participate in the conference call?
Investors can join the conference call by registering through the provided link and participating in the discussion.
What approvals does TULSA-PRO® have?
TULSA-PRO® is CE marked, approved by Health Canada, and has received 510(k) clearance from the U.S. FDA.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Investigating Claims Against Laser Photonics Corp. – LASE
- Global Military GNSS Receiver Market Insights and Forecast
- Acadia Pharmaceuticals Sets Q3 Financial Results Announcement
- Acadia Healthcare Lawsuit Update: Key Insights for Investors
- Xiao-I Corporation Faces Class Action Amid Financial Struggles
- Dominion DMS Unveils Innovative Cloud Solution for Dealers
- Nexus Industrial REIT Unveils Upcoming Financial Results and Distributions
- Infrastructure Dividend Split Corp. Boosts Shareholder Returns
- Berry Corporation Anticipates Q3 2024 Earnings Call Soon
- Nexus Industrial REIT Prepares for Upcoming Financial Release
Recent Articles
- Regency Affiliates Enhances Shareholder Value with Buyback
- Malibu Boats, Inc. Plans First Quarter Earnings Call for Investors
- Janus International Group Planning Q3 2024 Earnings Announcement
- BancFirst Corporation: Record Net Income in Latest Quarter
- MasterCraft Boat Company Reinvents Dealer Relations for Future Success
- Vir Biotechnology Plans Key Update: Q3 2024 Financial Insights
- Xavier Creative House Recognized Among America’s Healthiest Workplaces
- Tenaya Therapeutics Advances Gene Therapy Program for HCM
- Semrush Holdings, Inc. Scheduled Conference Call for Q3 2024
- Bandwidth Inc. Set to Discuss Third Quarter Financials Soon
- AYR Wellness Announces Third Quarter Conference Call Details
- United Bancshares Reports Impressive Q3 2024 Financial Gains
- Exciting Announcements Ahead for Cinemark's Q3 2024 Earnings
- Goosehead Insurance Set to Reveal Q3 2024 Financial Performance
- Lincoln Electric Boosts Dividend Amid Strong Business Performance
- Celebrate the Joy of Sunber Hair’s 7th Anniversary Sale
- Customers Bancorp Sets Date for Third Quarter 2024 Earnings Call
- Crown Holdings Sees Growth Amid Financial Challenges
- Sealed Air Announces Quarterly Dividend Contribution for Shareholders
- BlackSky Plans Q3 2024 Results Call to Discuss Insights
- Better Home & Finance Holding Company Prepares Third Quarter Report
- Huntington Bancshares Increases Cash Dividends for 2025
- SolarWinds Prepares for Q3 2024 Financial Results Announcement
- Centrus Energy Advances Domestic Uranium Enrichment Initiatives
- Intuitive Surgical Reports Strong Q3 Performance and Growth
- NYSE American Initiates Delisting of Calidi Biotherapeutics Warrants
- Quaker Houghton Schedules Earnings Call for Q3 2024
- AYR Wellness Announces Q3 2024 Earnings Call Details
- Genpact Limited Announces Exciting Dividend for Stakeholders
- United Bancshares Reports Strong Q3 2024 Performance
- Ansys Announces Upcoming Earnings Release - Q3 2024 Expectations
- McCormick & Company: Key Insights from Upcoming Investor Day
- Investor Alert: Fortrea Holdings Inc. Faces Investigative Scrutiny
- Patrick Industries Prepares for Q3 2024 Earnings Conference Call
- Regency Affiliates Strengthens Position with 331,500 Share Buyback
- Little Sunshine's Playhouse Expands in Denver Metro Area
- Richmond American Homes Celebrates Grand Opening of Timberline
- ALICORN Enhances Access to Virtual Primary Care Services
- VIAVI Solutions Set to Reveal Fiscal Q1 2025 Financials Soon
- Investigation Underway for Stitch Fix, Inc. Shareholders
- Hanford Tank Waste Operations & Closure Begins Cleanup Efforts
- Exciting Game Reveals from Xbox Partner Preview Event
- Fastenal Appoints New EVP of Strategy to Boost Growth
- Cynthia McCabe Steps Up as Exelon's Senior VP and Chief Officer
- Natalia Scherbakoff Takes Charge as Orion S.A. CTO
- Integrated Power Services Expands Reach with MDL Énergie Deal
- Agilon Health Schedules Third Quarter 2024 Financial Call
- GoHealth Shares Insights at Upcoming Investor Conference
- Cohu, Inc. Plans to Discuss Financial Results Soon
- Asure Software's Upcoming Q3 2024 Financial Results Announcement